Literature DB >> 20519343

Using functional genetics to understand breast cancer biology.

Alan Ashworth1, Rene Bernards.   

Abstract

Genetic screens were for long the prerogative of those that studied model organisms. The discovery in 2001 that gene silencing through RNA interference (RNAi) can also be brought about in mammalian cells paved the way for large scale loss-of-function genetic screens in higher organisms. In this article, we describe how functional genetic studies can help us understand the biology of breast cancer, how it can be used to identify novel targets for breast cancer therapy, and how it can help in the identification of those patients that are most likely to respond to a given therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20519343      PMCID: PMC2890198          DOI: 10.1101/cshperspect.a003327

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  35 in total

1.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells.

Authors:  Angelique W Whitehurst; Brian O Bodemann; Jessica Cardenas; Deborah Ferguson; Luc Girard; Michael Peyton; John D Minna; Carolyn Michnoff; Weihua Hao; Michael G Roth; Xian-Jin Xie; Michael A White
Journal:  Nature       Date:  2007-04-12       Impact factor: 49.962

2.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.

Authors:  Jason Moffat; Dorre A Grueneberg; Xiaoping Yang; So Young Kim; Angela M Kloepfer; Gregory Hinkle; Bruno Piqani; Thomas M Eisenhaure; Biao Luo; Jennifer K Grenier; Anne E Carpenter; Shi Yin Foo; Sheila A Stewart; Brent R Stockwell; Nir Hacohen; William C Hahn; Eric S Lander; David M Sabatini; David E Root
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

4.  Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance.

Authors:  Jeffrey P MacKeigan; Leon O Murphy; John Blenis
Journal:  Nat Cell Biol       Date:  2005-05-01       Impact factor: 28.824

5.  Integrative genomic approaches identify IKBKE as a breast cancer oncogene.

Authors:  Jesse S Boehm; Jean J Zhao; Jun Yao; So Young Kim; Ron Firestein; Ian F Dunn; Sarah K Sjostrom; Levi A Garraway; Stanislawa Weremowicz; Andrea L Richardson; Heidi Greulich; Carly J Stewart; Laura A Mulvey; Rhine R Shen; Lauren Ambrogio; Tomoko Hirozane-Kishikawa; David E Hill; Marc Vidal; Matthew Meyerson; Jennifer K Grenier; Greg Hinkle; David E Root; Thomas M Roberts; Eric S Lander; Kornelia Polyak; William C Hahn
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

6.  A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene.

Authors:  Stephane Gobeil; Xiaochun Zhu; Charles J Doillon; Michael R Green
Journal:  Genes Dev       Date:  2008-11-01       Impact factor: 11.361

7.  Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.

Authors:  Claudia Scholl; Stefan Fröhling; Ian F Dunn; Anna C Schinzel; David A Barbie; So Young Kim; Serena J Silver; Pablo Tamayo; Raymond C Wadlow; Sridhar Ramaswamy; Konstanze Döhner; Lars Bullinger; Peter Sandy; Jesse S Boehm; David E Root; Tyler Jacks; William C Hahn; D Gary Gilliland
Journal:  Cell       Date:  2009-05-29       Impact factor: 41.582

8.  CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.

Authors:  Ron Firestein; Adam J Bass; So Young Kim; Ian F Dunn; Serena J Silver; Isil Guney; Ellen Freed; Azra H Ligon; Natalie Vena; Shuji Ogino; Milan G Chheda; Pablo Tamayo; Stephen Finn; Yashaswi Shrestha; Jesse S Boehm; Supriya Jain; Emeric Bojarski; Craig Mermel; Jordi Barretina; Jennifer A Chan; Jose Baselga; Josep Tabernero; David E Root; Charles S Fuchs; Massimo Loda; Ramesh A Shivdasani; Matthew Meyerson; William C Hahn
Journal:  Nature       Date:  2008-09-14       Impact factor: 49.962

9.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway.

Authors:  Katrien Berns; E Marielle Hijmans; Jasper Mullenders; Thijn R Brummelkamp; Arno Velds; Mike Heimerikx; Ron M Kerkhoven; Mandy Madiredjo; Wouter Nijkamp; Britta Weigelt; Reuven Agami; Wei Ge; Guy Cavet; Peter S Linsley; Roderick L Beijersbergen; René Bernards
Journal:  Nature       Date:  2004-03-25       Impact factor: 49.962

10.  Cancer proliferation gene discovery through functional genomics.

Authors:  Michael R Schlabach; Ji Luo; Nicole L Solimini; Guang Hu; Qikai Xu; Mamie Z Li; Zhenming Zhao; Agata Smogorzewska; Mathew E Sowa; Xiaolu L Ang; Thomas F Westbrook; Anthony C Liang; Kenneth Chang; Jennifer A Hackett; J Wade Harper; Gregory J Hannon; Stephen J Elledge
Journal:  Science       Date:  2008-02-01       Impact factor: 47.728

View more
  13 in total

1.  On using functional genetics to understand breast cancer biology.

Authors:  Kornelia Polyak
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-07-01       Impact factor: 10.005

Review 2.  Drosophila RNAi screening in a postgenomic world.

Authors:  Chris Bakal
Journal:  Brief Funct Genomics       Date:  2011-07-12       Impact factor: 4.241

3.  Large-Scale RNA Interference Screening to Identify Transcriptional Regulators of a Tumor Suppressor Gene.

Authors:  Matteo Forloni; Thuy Ho; Lisha Sun; Narendra Wajapeyee
Journal:  Methods Mol Biol       Date:  2017

4.  Transcriptional Analysis-Based Integrative Genomics Approach to Identify Tumor-Promoting Metabolic Genes.

Authors:  Romi Gupta; Narendra Wajapeyee
Journal:  Methods Mol Biol       Date:  2017

5.  Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.

Authors:  Worapol Ngamcherdtrakul; Jingga Morry; Shenda Gu; David J Castro; Shaun M Goodyear; Thanapon Sangvanich; Moataz M Reda; Richard Lee; Samuel A Mihelic; Brandon L Beckman; Zhi Hu; Joe W Gray; Wassana Yantasee
Journal:  Adv Funct Mater       Date:  2015-05-13       Impact factor: 18.808

6.  Challenges translating breast cancer gene signatures into the clinic.

Authors:  Britta Weigelt; Lajos Pusztai; Alan Ashworth; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2011-08-30       Impact factor: 66.675

Review 7.  Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration.

Authors:  Daniel J Cooper; Giulia Zunino; John L Bixby; Vance P Lemmon
Journal:  Mol Cell Neurosci       Date:  2016-07-18       Impact factor: 4.314

8.  ALK Inhibitors, a Pharmaceutical Perspective.

Authors:  Elena Ardini; Arturo Galvani
Journal:  Front Oncol       Date:  2012-02-22       Impact factor: 6.244

9.  CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.

Authors:  Chun-Hao Huang; Amaia Lujambio; Johannes Zuber; Darjus F Tschaharganeh; Michael G Doran; Michael J Evans; Thomas Kitzing; Nan Zhu; Elisa de Stanchina; Charles L Sawyers; Scott A Armstrong; Jason S Lewis; Charles J Sherr; Scott W Lowe
Journal:  Genes Dev       Date:  2014-08-15       Impact factor: 11.361

10.  Loss of telomere protection: consequences and opportunities.

Authors:  Jacqueline J L Jacobs
Journal:  Front Oncol       Date:  2013-04-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.